Haemonetics (HAE) Other Accumulated Expenses (2010 - 2026)

Haemonetics has reported Other Accumulated Expenses for 17 years, with the latest figure at $163.8 million in Q2 2026.

• On a quarterly basis, Other Accumulated Expenses rose 12.46% year-over-year to $163.8 million in Q2 2026; TTM through Jun 2026 was $163.8 million, a 12.46% increase from a year earlier, with the FY2026 full-year figure at $158.3 million, up 6.89% from the prior year.
• Other Accumulated Expenses was $163.8 million for Q2 2026 at Haemonetics, up from $158.3 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $163.8 million in Q2 2026, with the low at $85.3 million in Q3 2022.
• Average Other Accumulated Expenses over 5 years is $129.2 million, with a median of $134.0 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses sank 33.26% in 2022, then soared 31.6% in 2023.
• Over 5 years, Other Accumulated Expenses stood at $101.0 million in 2022, then jumped by 31.12% to $132.4 million in 2023, then grew by 5.15% to $139.2 million in 2024, then dropped by 3.52% to $134.3 million in 2025, then climbed by 21.94% to $163.8 million in 2026.
• The last three Other Accumulated Expenses figures came in at $163.8 million (Q2 2026), $158.3 million (Q1 2026), and $134.3 million (Q4 2025), per Business Quant data.